Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
IDXX • Stock • Health Care / Health Care Equipment
Cross-Horizon Read
IDXX's evidence points supportive across the available windows.
Generated 2026-10-05T11:30:00.000Z • Evidence ad50780f
Price Data
Quote and historical price data are unavailable right now.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
4
Opposing articles
0
Neutral articles
11
Confidence basis
Supporting evidence
• IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unpacking a 26.86% Potential Upside in the Diagnostics & Research Sector
• IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
• Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
• Here is Why Growth Investors Should Buy Idexx (IDXX) Now
Opposing evidence
No opposing articles were found in this window.
Catalysts
• IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
• IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unpacking a 26.86% Potential Upside in the Diagnostics & Research Sector
• IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Analysts
• BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $665
• IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
Risks
• IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
• Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
• BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $665
• Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
• IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (4) grows relative to opposing evidence (0) in this window.
• The most recent evidence in this window is not very fresh is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (4) in this window.
Showing 8 of 15 sources
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Yahoo • 2026-08-20 • Mixed
Open via Finnhub →Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
Yahoo • 2026-08-19 • Mixed
Open via Finnhub →IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
SeekingAlpha • 2026-08-18 • Neutral
Open via Finnhub →IDEXX Laboratories (IDXX) Could Be 22% Undervalued As New Cardiac Test Expands Its Reach
Sahm • 2026-08-18 • Mixed
View source →IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unpacking a 26.86% Potential Upside in the Diagnostics & Research Sector
DirectorsTalk Interviews • 2026-08-17 • Bullish
View source →IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Analysts
MarketBeat • 2026-08-16 • Neutral
View source →BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $665
Moomoo • 2026-08-15 • Neutral
View source →IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
TradingKey • 2026-08-14 • Bullish
View source →